{"id":"W2767905976","doi":"10.1016/j.jtho.2017.09.429","title":"OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Pemetrexed; Carboplatin; Chemotherapy; Gemcitabine; Internal medicine; Oncology; Cisplatin; Neutropenia; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001500277,0.0005402396,0.001699501,0.001230243,0.0001761816,0.001252847,0.00121497,0.0008771163,0.003422215],"category_scores_gemma":[0.003879059,0.0003017986,0.001316116,0.001232896,0.0002173728,0.001032174,0.0004941873,0.001997811,0.00125907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001357209,"about_ca_system_score_gemma":0.001481722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003046196,"about_ca_topic_score_gemma":0.01359983,"domain_scores_codex":[0.9995853,0.00006681318,0.00007633506,0.00005419103,0.0001695872,0.00004768679],"domain_scores_gemma":[0.9981785,0.0006209358,0.0004568971,0.00005087894,0.0004868664,0.0002058733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.001149658,0.0001550511,0.005796268,0.003892618,0.0006889724,0.0002181349,0.00004158468,0.001305878,0.001431273,0.0006152117,0.1108335,0.8738718],"study_design_scores_gemma":[0.001503523,0.001792857,0.02895852,0.005784282,0.003915623,0.00263147,0.00007212875,0.001921052,0.001444096,0.0008106222,0.9510871,0.00007869552],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.02019513,0.9322539,0.001871548,0.01389285,0.005384339,0.0002039562,0.005493283,0.0004565983,0.02024845],"genre_scores_gemma":[0.07812927,0.8662552,0.005056767,0.02061427,0.00637778,0.0002760319,0.01382299,0.0001837084,0.009283953],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.003422215,"threshold_uncertainty_score":0.01144838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03107285707539334,"score_gpt":0.405095841046255,"score_spread":0.3740229839708616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}